[]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : OCS-01 is developed using the Optireach® solubilizing technology, a proprietary platform that enables the formulation of drugs as topical eye drop treatment with cystoid macular edema.

                          Product Name : OCS-01

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 08, 2023

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The proceeds expected to support advanced clinical pipeline of multiple innovative products, potentially including the first topical eye-drop for OCS-01 (dexamethasone), the first biologic eye-drop for DED and the first neuroprotective agent for neuro-re...

                          Product Name : OCS-01

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          October 17, 2022

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : European Biotech Acquisition Corp

                          Deal Size : $80.0 million

                          Deal Type : Merger

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Dataset shows that OCS-01 (dexamethasone) eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.

                          Product Name : OCS-01

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          June 09, 2022

                          Lead Product(s) : Dexamethasone

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank